ACRUX LIMITED

0.00%

1.0¢

Market Cap $5.896M

Healthcare

Acrux Limited is a drug development company. The Company is engaged in developing and... Acrux Limited is a drug development company. The Company is engaged in developing and commercializing branded and generic transdermal and topical pharmaceuticals for global markets. The Company's transdermal or topical pharmaceutical product portfolio can be segregated into approximately two streams, such as generic pharmaceutical products and specialty pharmaceutical products. The Company's products include Axiron, Ellavie, Evamist and Lenzetto. Axiron (testosterone) topical solution CIII is a testosterone topical solution approved for application via an armpit (underarm) applicator. It has developed the estradiol spray for women, used to treat moderate to severe hot flushes commonly associated with menopause. In the United States, the Company's estradiol spray is branded Evamist. The Company has licensed its estradiol product to Gedeon Richter to commercialize in various territories, including Europe and Eurasia. Gedeon Richter has branded the estradiol spray as Lenzetto.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Latest Threads

Tag

Subject

ACR

Ann: Becoming a substantial holder

12/04/18

2.2K

12/04/18

Last post brushup

2.2K

ACR

Small Caps Presentation

08/04/18

579

08/04/18

Last post brushup

579

ACR

Ann: Correction Half-Year Financial Report 31 December 2017

29/03/18

655

29/03/18

Last post brushup

655

ACR

Ann: Appendix 4D and Half-Year Report to 31 December 2017

16/03/18

3.2K

16/03/18

Last post brushup

3.2K

ACR

Ann: Change of Director's Interest Notice

26/02/18

170

26/02/18

Last post

ASX News

170

See All Discussions

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last 1.0¢		Change 0.000(0.00%)		Mkt cap ! $5.896M

Open	High	Low	Volume
0.0¢	0.0¢	0.0¢	0

Buyers (Bids)

Vol.	Price($)
3290740	0.9¢

Sellers (Offers)

Price($)	Vol.
1.0¢	1615459

Last trade - 09.38am 18/08/2026 (20 minute delay)

ACR (ASX) Chart

Day chart unavailable

ACRUX LIMITED

Corporate Spotlight
Not Yet Available

Latest Threads

Latest Articles

Acrux scores fourth FDA approval, Nitroglycerin Ointment moving into commercialisation

Acrux Ltd has achieved the fourth approval from the US FDA, with its Nitroglycerin Ointment 0.4%, ready for commercialisation

US FDA approves review of Acrux (ASX:ACR) nitroglycerin ointment

Acrux (ASX:ACR) has received approval from the US FDA to review a generic version of its nitroglycerin ointment at 0.4 per cent concentration.

Acrux (ASX:ACR) announces buyout of future Lenzetto royalties

Pharmaceutical company Acrux (ACR) has reached an agreement for the EUR 4.10 million (A$6.41 million) buyout of future royalties for the company's Lenzetto product.

Buyers (Bids)

Sellers (Offers)

Top Stories

ACRUX LIMITED

Corporate SpotlightNot Yet Available

Latest Threads

Latest Articles

Acrux scores fourth FDA approval, Nitroglycerin Ointment moving into commercialisation

Acrux Ltd has achieved the fourth approval from the US FDA, with its Nitroglycerin Ointment 0.4%, ready for commercialisation

US FDA approves review of Acrux (ASX:ACR) nitroglycerin ointment

Acrux (ASX:ACR) has received approval from the US FDA to review a generic version of its nitroglycerin ointment at 0.4 per cent concentration.

Acrux (ASX:ACR) announces buyout of future Lenzetto royalties

Pharmaceutical company Acrux (ACR) has reached an agreement for the EUR 4.10 million (A$6.41 million) buyout of future royalties for the company's Lenzetto product.

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available